ArticleTranslational cancer research2019
Five tumor-associated autoantibodies expression levels in serum predict lung cancer and associate with poor outcome.
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- The early diagnostic value of lung cancer autoantibodies and tumor markers in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Tumor antigen-associated autoantibodies: generation mechanisms, roles in tumorigenesis and progression, and clinical application prospects.Frontiers in immunology · 2026Review
- Longitudinal monitoring of autoantibody dynamics in patients with early-stage non-small-cell lung cancer undergoing surgery.Open life sciences · 2025Article
- Association between high-density lipoprotein cholesterol and 7-autoantibodies: a study on physical examination data from 2018 to 2023.Frontiers in endocrinology · 2025Article
- Machine Learning for Early Discrimination Between Lung Cancer and Benign Nodules Using Routine Clinical and Laboratory Data.Annals of surgical oncology · 2024Observational
- An analysis of the influencing factors of false negative autoantibodies in patients with non-small cell lung cancer.Frontiers in oncology · 2024Article
- Improvement in the performance of an autoantibody panel in combination with heat shock protein 90a for the detection of early‑stage lung cancer.Experimental and therapeutic medicine · 2023Article
- The combination of a seven-autoantibody panel with computed tomography scanning can enhance the diagnostic efficiency of non-small cell lung cancer.Frontiers in oncology · 2022Article
- Autoantibodies - enemies, and/or potential allies?Frontiers in immunology · 2022Review
- The role of autoantibody detection in the diagnosis and staging of lung cancer.Annals of translational medicine · 2021Article
- The diagnostic value of a seven-autoantibody panel and a nomogram with a scoring table for predicting the risk of non-small-cell lung cancer.Cancer science · 2020Article
- Recommended changes for the 8th edition of the TNM classification for lung cancer-the findings of a single-institution evaluation.Annals of translational medicine · 2020Article
- External validation of the eighth edition of the TNM classification for lung cancer in 3,611 surgically treated patients at a single institution.Annals of translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to evaluate diagnostic feasibility of the tumor-associated autoantibodies and their clinical significance in lung cancer.
methodsBlood samples were collected from 352 lung cancer patients and 226 healthy individuals. Immunohistochemical staining was used to evaluate the expression of autoantibodies in 69 cases of lung cancer tissues. Enzyme-linked immunosorbent assay (ELISA) was performed to measure the five autoantibodies levels in serum from lung cancer patients and healthy controls.
resultsHigher expression of GAGE7, MAGEA1, PGP9.5, CAGE and p53 were found in lung cancer tissues than normal tissues from the cancer genome atlas (TCGA) database. The expression levels of the five tumor-associated autoantibodies in lung cancer tissues were positively associated with those statuses in serum. There were significantly higher levels of each autoantibody in lung cancer patients than healthy individuals. The area under curve (AUC) for GAGE7, MAGEA1, PGP9.5, CAGE and p53 in diagnosis of lung cancer were 0.787, 0.641, 0.873, 0.825 and 0.749, respectively. With combination of these five autoantibodies by the logistic regression model, 0.891 of AUC was shown. In addition, the level of each autoantibody was increased in the advanced stage. Particularly, the level of PGP9.5 was significantly higher in the advanced T stage, N stage and TNM stage and CAGE was significantly elevated in the advanced N stage.
conclusionsSummarily, autoantibodies levels of GAGE7, MAGEA1, PGP9.5, CAGE and p53 in serum could be used for the diagnosis of lung cancer and PGP9.5 may predict poor prognosis for the patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.